Get the Stockscreener App
0.5988
3.48%
-0.0216
After Hours:
.59
-0.0088
-1.47%
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - Stocks Register
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter
CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - TipRanks
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights
Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks
CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks
CytomX To Report Colorectal Cancer Trial Data Of CX-2051 In 1H, 2025 - Nasdaq
CytomX Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue By Investing.com - Investing.com UK
CYTOMX THERAPEUTICS Earnings Results: $CTMX Reports Quarterly Earnings - Nasdaq
CytomX Therapeutics Inc Reports Q4 EPS of $0.38 and Revenue of $138.1 Million, Surpassing Estimates - GuruFocus.com
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics Advances CX-2051 and CX-801 Programs, Reports Strengthened Financial Position - Nasdaq
CytomX stock plunges to 52-week low, touches $0.6 - Investing.com India
Daily Progress: CytomX Therapeutics Inc (CTMX) Drop -5.76, Closing at 0.62 - The Dwinnex
10 Cheap Growth Stocks to Buy Now - Insider Monkey
CytomX Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect? - MSN
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Can CytomX's Conference Presentation Reveal New Strategic Directions for Its Masked Biologics Platform? - StockTitan
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result - Yahoo Finance
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times
When Will CytomX Release Q4 2024 Results? Key Date for Biotech Investors - StockTitan
CytomX faces Nasdaq delisting over share price woes - Investing.com India
CytomX faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com Nigeria
CytomX stock hits 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):